艾力斯：公司高度重视产品研发

Core Insights - The company places a high emphasis on product research and development, with multiple clinical registrations for its core product, Furmetinib, currently in progress [1] Group 1: Product Development - Furmetinib has received approval for multiple indications, including second-line and first-line treatments, with additional clinical registrations underway for various mutations and conditions [1] - The NDA application for second-line treatment of the 20 exon mutation has been accepted and prioritized for review [1] - The PACC mutation NSCLC first-line treatment indication has been included as a potential breakthrough therapy for December 2025 [1] Group 2: New Product Introductions - In August 2024, the company introduced KRAS G12C inhibitor, Goretinib, and SHP2 inhibitor, AST24082, taking full responsibility for their subsequent development [1] - Goretinib's second-line treatment for NSCLC has been officially approved as of May 2025, with ongoing studies for pancreatic cancer and other solid tumors [1] - Clinical trials for the combination of Goretinib and AST24082 for first-line treatment of KRAS G12C mutation NSCLC are progressing smoothly [1] Group 3: Ongoing Research and Development - The company is conducting a Phase I clinical trial for a next-generation EGFR-TKI targeting C797S mutation NSCLC patients [1] - The new drug discovery platform has been enhanced, covering both large and small molecule research, with several innovative drugs in preclinical development [1]